Market capitalization | HKD110.26b |
Enterprise Value | HKD85.14b |
P/E (TTM) P/E ratio | 21.58 |
EV/FCF (TTM) EV/FCF | 16.06 |
EV/Sales (TTM) EV/Sales | 6.50 |
P/S ratio (TTM) P/S ratio | 8.42 |
P/B ratio (TTM) P/B ratio | 3.68 |
Dividend yield | 1.85% |
Last dividend (FY23) | HKD0.34 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
22 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:
22 Analysts have issued a Hansoh Pharmaceutical Group Company forecast:
Jun '24 |
+/-
%
|
||
Revenue | 13,091 13,091 |
23%
23%
|
|
Gross Profit | 11,929 11,929 |
25%
25%
|
|
EBITDA | 5,093 5,093 |
64%
64%
|
EBIT (Operating Income) EBIT | 4,662 4,662 |
73%
73%
|
Net Profit | 5,102 5,102 |
76%
76%
|
In millions HKD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Hansoh Pharmaceutical Group Co., Ltd. is a holding company, which engages in the research and development, production, and sale of a series of pharmaceutical products. Its products include oncology, anti-infective, anti-diabetic, gastrointestinal, and cardiovascular drugs. The company was founded by Huijuan Zhong on December 2, 2015 and is headquartered in Lianyungang, China.
Head office | Cayman Islands |
CEO | Hui Zhong |
Employees | 9,123 |
Founded | 2015 |
Website | www.hspharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.